La Roche-Posay CEO Net Worth

Last Updated Mar 10, 2025
CEO NameMyriam Cohen-Welgryn
NationalityFrance
Net Worth Estimation$5 million

Myriam Cohen-Welgryn's estimated net worth of around $5 million USD is primarily attributed to her executive compensation, equity, and bonuses as current CEO of La Roche-Posay, a leading dermatological skincare brand under L'Oreal Group. Her previous leadership roles at Danone, Mars, and Procter & Gamble also contribute significantly to her accumulated wealth.

Myriam Cohen-Welgryn, CEO of La Roche-Posay, has an estimated net worth of $5,000,000, which is 4.49% of the maximum ($90,000,000) and 500% of the minimum ($1,000,000) net worth in the personal care business category. Her net worth positions her well above the minimum but significantly below the maximum among CEOs in this sector.

Business Category: Personal care

Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 90000000 USD


Myriam Cohen-Welgryn Performance in La Roche-Posay

Myriam Cohen-Welgryn, CEO of La Roche-Posay, demonstrates strategic leadership focused on innovation and sustainability in skincare. Her decisive management style drives product development and global market expansion, enhancing brand reputation and consumer trust. Under her leadership, La Roche-Posay has seen improved performance with increased sales growth and strengthened commitment to dermatological research.


Latest News

La Roche-Posay's Growth Strategy and CEO Leadership in 2025

La Roche-Posay, a L'Oreal-owned dermatological skincare brand, aims to reach EUR3 billion in sales in 2025 by focusing on innovation in acne care, neuroscience, and microbiome science. The CEO of L'Oreal Australia & New Zealand, Alex Davison, highlighted the brand's partnerships in skin cancer awareness and melanoma research as key initiatives supporting its dermatological leadership and mission to improve skin health globally.
Source: http://cosmeticsbusiness.com/la-roche-posay-to-rule-dermo-cosmetics-and-make-3-billion-this-year



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about La Roche-Posay are subject to change from time to time.

Comments

No comment yet